Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma
Not Applicable
Completed
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Procedure: CSF analysis
- Registration Number
- NCT01202448
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
This study is to evaluate the incidence of central nervous system (CNS) relapse or metastasis in patients with diffuse large B-cell lymphoma.
- Detailed Description
We dichotomize patients according to the risk of CNS involvement. Then, we perform CNS evaluation in patients at risk of CNS involvement. We prospectively monitor whether CNS relapse or metastasis occurs in patients with diffuse large B-cell lymphoma
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
- Newly diagnosed patients with diffuse large B cell lymphoma
- > 20 years
- life expectancy more than 6 months
- Written informed consent
Exclusion Criteria
- Refusal to informed consent
- Lymphomas other than diffuse large B cell lymphoma
- Primary CNS lymphoma
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description DLBCL with risk factor CSF analysis Patients have any of risk factors for secondary CNS involvement
- Primary Outcome Measures
Name Time Method CNS relapse/involvement Up to 2 years after participants are enrolled. After enrollment, patients will be monitored to check the CNS relapse or involvement
- Secondary Outcome Measures
Name Time Method survival Up to 2 years after participants are enrolled The survival outcome of patients will be monitored.
Trial Locations
- Locations (2)
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of